Your session is about to expire
← Back to Search
Haploidentical Bone Marrow Transplant for Aplastic Anemia
Study Summary
This trial is testing a new treatment for severe aplastic anemia, which is a rare and serious form of bone marrow failure. The new treatment is using a haploidentical donor for transplantation, which has good response rates and significantly lower rates of acute and chronic GVHD.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lung function is significantly reduced.My liver is not functioning well (bilirubin >= 2mg/dL).I have a family donor who matches 3/6 to 5/6 of my HLA markers and we are compatible.I am 65 or younger if untreated, and 75 or younger if previously treated.I am mostly able to care for myself.My condition is diagnosed as Aplastic Anemia with specific blood and bone marrow findings.I have had a transplant from a donor.My kidney function is poor, with high creatinine or low clearance.My heart's pumping ability is below 40%.
- Group 1: Flu/Cy/TBI
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any potential risks associated with Fludarabine usage?
"While Fludarabine has been tested in preliminary clinical trials, there is limited data available to confirm its efficacy. As such, our team at Power assigned it a safety score of 2."
What is the current capacity for participants in this medical experiment?
"Correct. An analysis of the data on clinicaltrials.gov demonstrates that this medical experiment, initially posted September 9th 2016, is presently enrolling participants; with 20 individuals being sought from 2 separate facilities."
Has Fludarabine been previously studied in other experiments?
"Presently, there are 906 active clinical studies of Fludarabine with 163 in the final phase. According to current data, most trials for this medication are conducted in Philadelphia while 28490 sites around the world have opened their doors to further research on this drug."
What criteria must individuals fulfill to participate in this investigation?
"To be considered, patients must suffer from anemia and aplastic anemia; additionally, they should be between 1 year and 75 years old. Notably, only 20 people are being recruited into this trial."
What are the primary applications of Fludarabine as a therapeutic agent?
"Fludarabine is often used for immunosuppression, but has also been prescribed to treat multiple sclerosis, leukemia, myelocytic and acute leukemias as well as retinoblastoma."
Is this research endeavor open to adults aged 18 and above?
"This medical trial is accepting patients who are between 1 year and 75 years of age."
Are there any vacant spaces left for participants in this clinical trial?
"The data on clinicaltrials.gov indicates that the recruitment process is still in progress. The trial was first released to the public domain on September 9th 2016 and revised lastly on October 19th 2022."
Share this study with friends
Copy Link
Messenger